Scholarlink

Background <p>To date, the population-based cardiovascular mortality (CVM) of metastatic melanoma has not been studied in the era of immune checkpoint inhibitors (ICIs). This study aims to assess the risk of CVM in patients with metastatic melanoma in the pre-ICI (2000–2010) and post-ICI (2011–2020) eras.</p> Methods <p>This study using the Surveillance, Epidemiology, and End Results database from 2000 to 2020 of patients with metastatic melanoma. Standardized mortality ratios (SMRs) and absolute excess risks were calculated for CVM before and after the introduction of ICIs. To evaluate the cumulative mortality (CM) rate for all causes of death, cumulative hazard curves were constructed. Competing risk models were established to determine the independent predictors for CVM.</p> Results <p>This study included 8857 patients, 3803 in the pre-ICI era and 5054 in the post-ICI era. A total of 281 deaths were attributed to cardiovascular diseases. The overall SMRs of CVM were 27% higher (SMR = 1.27, 95% CI 1.06–1.50) in the pre-ICI era and 56% higher (SMR = 1.56, 95% CI 1.31–1.83) in the post-ICI era than the general population, reaching 2.17 during the early stage of latency (0–5&#xa0;months). Additionally, independent risk factors for CVM included age, primary site, and brain metastases in the post-ICI era.</p> Conclusions <p>Metastatic melanoma patients exhibited an elevated CVM risk after the approval of ICIs, peaking in early latency period and older population. Timely monitoring and effective interventions for cardiovascular diseases may be warranted in patients with metastatic melanoma, especially in the immunotherapy era.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cardiovascular disease mortality risk among patients with metastatic melanoma before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and End Results database-based study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月15日

查看全文
  • Xiaoqin Luo,
  • Jiaying Niu,
  • Yufeng Zhang,
  • Yanni Jia,
  • Qiannan Wang,
  • Yuanyuan Li,
  • Yonghuan Wang,
  • Jinglian Li,
  • Zhenhua Li,
  • Rui Yan,
  • Sijin Li

摘要

Background

To date, the population-based cardiovascular mortality (CVM) of metastatic melanoma has not been studied in the era of immune checkpoint inhibitors (ICIs). This study aims to assess the risk of CVM in patients with metastatic melanoma in the pre-ICI (2000–2010) and post-ICI (2011–2020) eras.

Methods

This study using the Surveillance, Epidemiology, and End Results database from 2000 to 2020 of patients with metastatic melanoma. Standardized mortality ratios (SMRs) and absolute excess risks were calculated for CVM before and after the introduction of ICIs. To evaluate the cumulative mortality (CM) rate for all causes of death, cumulative hazard curves were constructed. Competing risk models were established to determine the independent predictors for CVM.

Results

This study included 8857 patients, 3803 in the pre-ICI era and 5054 in the post-ICI era. A total of 281 deaths were attributed to cardiovascular diseases. The overall SMRs of CVM were 27% higher (SMR = 1.27, 95% CI 1.06–1.50) in the pre-ICI era and 56% higher (SMR = 1.56, 95% CI 1.31–1.83) in the post-ICI era than the general population, reaching 2.17 during the early stage of latency (0–5 months). Additionally, independent risk factors for CVM included age, primary site, and brain metastases in the post-ICI era.

Conclusions

Metastatic melanoma patients exhibited an elevated CVM risk after the approval of ICIs, peaking in early latency period and older population. Timely monitoring and effective interventions for cardiovascular diseases may be warranted in patients with metastatic melanoma, especially in the immunotherapy era.